Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
miR-31-3p/5p in PETACC-8
NCT03362684Phase 3Completed
- Sponsor
- IntegraGen
- Start
- Nov 2005
- Primary completion
- Nov 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial of cetuximab in colon cancer (2 arms), sponsored by IntegraGen. Primary endpoints: Disease Free Survival at 7 years and Prognostic and predictive value of miR-31-3p expression on Disease Free Survival at 7 years. Started Nov 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT03362684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03362684.